secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cryoport, Inc. (CYRX)
CIK:        0001124524
Form:       8-K
Filed at:   2021-08-05T23:59:59+00:00
Accession:  0001104659-21-100827
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cryoport Q2 revenue $56.2M (+498% YoY); record trials, positive adjusted EBITDA
-------------------------------------------------------------------------------

- Revenue $56.2M, up 498% YoY; organic growth 55%; Biopharma/Pharma up 431%.
- Net loss $5.4M vs $5.8M loss a year ago; net loss per share $0.16 vs $0.15.
- Adjusted EBITDA $5.9M vs ($2.5M) loss; gross margin 45.2% vs 54.6%.
- Supporting 561 clinical trials and 8 commercial therapies; acquired F-airGate and CTSA in Q2.
- Cash $349.4M after public offering; expects up to 9 MAA/BLA filings in H2 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124524/000110465921100827/0001104659-21-100827-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124524/000110465921100827/tm2124288d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-100827

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer